KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Acadia Pharmaceuticals (ACAD) Return on Capital Employed (2016 - 2025)

Acadia Pharmaceuticals has reported Return on Capital Employed over the past 15 years, most recently at 8.96% for Q4 2025.

  • For Q4 2025, Return on Capital Employed fell 2462.0% year-over-year to 8.96%; the TTM value through Dec 2025 reached 8.96%, down 2462.0%, while the annual FY2025 figure was 9.54%, 3071.0% down from the prior year.
  • Return on Capital Employed for Q4 2025 was 8.96% at Acadia Pharmaceuticals, down from 26.14% in the prior quarter.
  • Over five years, Return on Capital Employed peaked at 33.57% in Q4 2024 and troughed at 45.25% in Q3 2022.
  • A 5-year average of 0.99% and a median of 3.93% in 2023 define the central range for Return on Capital Employed.
  • Biggest five-year swings in Return on Capital Employed: tumbled -5072bps in 2022 and later soared 5238bps in 2023.
  • Year by year, Return on Capital Employed stood at 27.81% in 2021, then surged by 66bps to 9.55% in 2022, then tumbled by -76bps to 16.81% in 2023, then soared by 300bps to 33.57% in 2024, then crashed by -73bps to 8.96% in 2025.
  • Business Quant data shows Return on Capital Employed for ACAD at 8.96% in Q4 2025, 26.14% in Q3 2025, and 27.9% in Q2 2025.